ImmunityBio, Inc.

NASDAQ:IBRX

2.41 (USD) • At close September 8, 2025
Bedrijfsnaam ImmunityBio, Inc.
Symbool IBRX
Munteenheid USD
Prijs 2.41
Beurswaarde 2,278,064,550
Dividendpercentage 0%
52-weken bereik 1.83 - 7.48
Industrie Biotechnology
Sector Healthcare
CEO Mr. Richard Gerald Adcock
Website https://immunitybio.com

An error occurred while fetching data.

Over ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in

Vergelijkbare Aandelen

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

145.2 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

38.245 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

114.36 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

21.2 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

38.19 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

165.86 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

9.7 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

0.432 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

45.82 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)